These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21951273)

  • 1. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.
    Couvineau A; Laburthe M
    Br J Pharmacol; 2012 May; 166(1):42-50. PubMed ID: 21951273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VPAC1 receptor binding site: contribution of photoaffinity labeling approach.
    Couvineau A; Ceraudo E; Tan YV; Laburthe M
    Neuropeptides; 2010 Apr; 44(2):127-32. PubMed ID: 20031208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The VPAC1 receptor: structure and function of a class B GPCR prototype.
    Couvineau A; Ceraudo E; Tan YV; Nicole P; Laburthe M
    Front Endocrinol (Lausanne); 2012; 3():139. PubMed ID: 23162538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
    Nicole P; Lins L; Rouyer-Fessard C; Drouot C; Fulcrand P; Thomas A; Couvineau A; Martinez J; Brasseur R; Laburthe M
    J Biol Chem; 2000 Aug; 275(31):24003-12. PubMed ID: 10801840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors.
    Langer I; Latek D
    Front Endocrinol (Lausanne); 2021; 12():711906. PubMed ID: 34867774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.
    Ceraudo E; Murail S; Tan YV; Lacapère JJ; Neumann JM; Couvineau A; Laburthe M
    Mol Endocrinol; 2008 Jan; 22(1):147-55. PubMed ID: 17885205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs.
    Couvineau A; Tan YV; Ceraudo E; Laburthe M
    Methods Enzymol; 2013; 520():219-37. PubMed ID: 23332702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in the relative abundance of the vasoactive intestinal peptide receptors (VPAC1 and VPAC2) and functions in uterine contractility during inflammation.
    Palus K; Całka J; Jana B
    Anim Reprod Sci; 2021 Feb; 225():106680. PubMed ID: 33388613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling.
    Couvineau A; Tan YV; Ceraudo E; Lacapère JJ; Murail S; Neumann JM; Laburthe M
    Ann N Y Acad Sci; 2006 Jul; 1070():205-9. PubMed ID: 16888167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.
    Ceraudo E; Tan YV; Nicole P; Couvineau A; Laburthe M
    J Mol Neurosci; 2008 Nov; 36(1-3):245-8. PubMed ID: 18597186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP.
    Laburthe M; Couvineau A
    Regul Pept; 2002 Oct; 108(2-3):165-73. PubMed ID: 12220741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
    Nachtergael I; Gaspard N; Langlet C; Robberecht P; Langer I
    Cell Signal; 2006 Dec; 18(12):2121-30. PubMed ID: 16650965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling.
    Tan YV; Couvineau A; Murail S; Ceraudo E; Neumann JM; Lacapère JJ; Laburthe M
    J Biol Chem; 2006 May; 281(18):12792-8. PubMed ID: 16520374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and purification of large quantities of the functional N-terminal ectodomain of human VPAC1 receptor.
    Couvineau A; Robert JC; Ramdani T; Lacapère JJ; Rouyer-Fessard C; Laburthe M
    J Mol Neurosci; 2008 Nov; 36(1-3):249-53. PubMed ID: 18592417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Molecular Dynamics Study of Vasoactive Intestinal Peptide Receptor 1 and the Basis of Its Therapeutic Antagonism.
    Latek D; Langer I; Krzysko K; Charzewski L
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
    Yadav M; Huang MC; Goetzl EJ
    Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.
    Valdehita A; Bajo AM; Fernández-Martínez AB; Arenas MI; Vacas E; Valenzuela P; Ruíz-Villaespesa A; Prieto JC; Carmena MJ
    Peptides; 2010 Nov; 31(11):2035-45. PubMed ID: 20691743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.
    Harmar AJ; Fahrenkrug J; Gozes I; Laburthe M; May V; Pisegna JR; Vaudry D; Vaudry H; Waschek JA; Said SI
    Br J Pharmacol; 2012 May; 166(1):4-17. PubMed ID: 22289055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide and its receptors in human ovarian cortical follicles.
    Gabbay-Benziv R; Ao A; Fisch B; Zhang L; Oron G; Kessler-Icekson G; Ben-Haroush A; Krissi H; Abir R
    PLoS One; 2012; 7(5):e37015. PubMed ID: 22623971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.